MDV3100 for the treatment of prostate cancer.
Mukherji D, Pezaro CJ, De-Bono JS.
Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.651125 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för cabazitaxel. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
15 träffarNovel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Sartor O, Michels RM, Massard C, de Bono JS.
Oncologist · research-article; review; journal article · DOI 10.1634/theoncologist.2010-0412Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.
de Bruijn P, de Graan AJ, Nieuweboer A, Mathijssen RH, Lam MH, de Wit R, Wiemer EA, Loos WJ.
J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2011.10.010Recent advances in second-line treatment of castration-resistant prostate cancer.
Ong M, Ong M, Winquist E.
Curr Opin Support Palliat Care · research support, non-u.s. gov't; review; journal article · DOI 10.1097/spc.0b013e32834903aaEmerging treatment options for patients with castration-resistant prostate cancer.
George D, Moul JW.
Prostate · research support, non-u.s. gov't; review; journal article · DOI 10.1002/pros.21435Cabazitaxel: a novel microtubule inhibitor.
Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, Nguyen T, Cals L, Dobi E, Pivot X.
Drugs · review; journal article · DOI 10.2165/11591390-000000000-00000Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells.
Han B, Fujimoto N, Kobayashi M, Matsumoto T.
Prostate Cancer · research-article; journal article · DOI 10.1155/2012/989214Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.
Tsao CK, Seng S, Oh WK, Galsky MD.
Clin Med Insights Oncol · review-article; journal article · DOI 10.4137/cmo.s6566Contemporary management of metastatic castration-resistant prostate cancer.
Sonpavde G, Sternberg CN.
Curr Opin Urol · research support, non-u.s. gov't; review; journal article · DOI 10.1097/mou.0b013e3283449e19TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S.
Future Oncol · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.2217/fon.11.23Current treatment strategies for castration-resistant prostate cancer.
Kim SJ, Kim SI.
Korean J Urol · review-article; journal article · DOI 10.4111/kju.2011.52.3.157Cabazitaxel for the treatment of prostate cancer.
Michielsen DP, Braeckman JG, Denis L.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2011.567268Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ, Antonarakis ES.
Drug Des Devel Ther · review-article; review; journal article · DOI 10.2147/dddt.s13029A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, Dubin F, Semiond D, Pivot X.
Eur J Cancer · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/j.ejca.2011.01.001Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N, Sonpavde G, Sartor O.
Future Oncol · journal article · DOI 10.2217/fon.10.168